Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
1. purpose: To conduct the relative bioavailability study of a single dose and multiple
doses of imatinib mesylate capsule (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus
Glivec (Novartis Pharma Stein AG).
2. Experimental Design： Two-period crossover design
3. Test drug: imatinib mesylate capsule Reference drug: Glivec
4. Sample size：20
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd